Jazz Pharmaceuticals price target raised to $70 from $63 at WallachBeth WallachBeth raised its price target for Jazz Pharmaceuticals following the company's better than expected Q4 results and reiterates a Buy rating on the stock. The firm believes Jazz's outlook leaves room for upside.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Jazz Pharmaceuticals executing on all cylinders, says Stifel Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.